Even stranger when they become inverted spikes.
No broad strength at the close. Unless Keith "knocks it out of the park," we will see 8s tomorrow.
You can definitely make money "trading" this stock, but be careful. You'll see more realistic price levels in January (tax selling) and also because retail investors will be better educated on the true market value for tissue assays. That's been way over-hyped to-date, and there will be competition entering the market.
We see the same pattern happen time and time again with biotech start-ups.
The hype will likely last through December, but when profits can be sold for tax purposes in January you'll see a decline in the PPS.
That, plus a realization on the part of retail investors that the market size for this company is not nearly as big as originally purported. We see this same pattern repeated time again and again with biotech start-ups.
And ALL of the assay markets are predicted at only $500M market size. The liver assay market is about $200M of that. And ONVO won't get all of those markets. Competition will be appearing shortly.
ONVO is a nice story, but the irrational exuberance riding this stock higher will eventually face the reality of true market conditions.
And it took you years to become a jerk, too, right? These boards were created to share information; not for self aggrandizement. Sheesh.
It's unlikely that ONVO has cornered the patent market for this process, especially if you do your due diligence about them.
There will be a LOT of competition in this space. Sooner rather than later.
Amen. Some sanity finally here.
This is clearly a momentum trading stock (with zero fundamentals), but momentum can play both ways. In the short-term, the PPS will remaine extremely volatile in BOTH directions.
ONVO is a very good "story." Many of their proposed markets (e.g. transplants) are decade(s) away from actually being realized. As a person who is in need of a heart transplant, I realize this as much as anyone. I'm a realist and a pragmatist; timing is everything.
The tissue assay market is also much smaller than the $BILLIONS that people have been led to believe. And once we start to see other competitors enter the space, which is inevitable, then you'll see corresponding devaluation of ONVO.
"Stay thirsty my friends, but be careful what you drink."
You've got to be kidding, right?
What prospectus are you referring to?
If true, it tells me something about ONVO management.
ZERO proven products YET, sir... please get your facts straight.
They are shooting for the "end" of 2014 for their first liver assay product.
The amount of "irrational exuberance" with this stock is truly stunning. Speculation for transplant solutions which are decade(s) away.
The liver assay market is actually closer to $200M than the $500M that some have postulated and they won't begin realizing any revenue until late 2014. This company's market cap is currently way too high.
Long-term I'm bullish for this company and 3D bioprinting in general, but there is no "REAL" justification for the current market cap.
Is there a conference call on December 5th? What's happening that day?